Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.

Carlos King-Ho Wong Ivan Chi Ho AuWing Yiu ChengKenneth Keng Cheung Man Kristy Tsz Kwan Lau Loey Lung-Yi MakSing Leung LuiMatthew Shing Hin Chung Xi Xiong Eric Ho Yin Lau Benjamin John Cowling

Published in: Alimentary pharmacology & therapeutics (2022)

The increased risks of AKI and ALI associated with intravenous remdesivir treatment for COVID-19 may be due to the underlying SARS-CoV-2 infection. The risks of AKI and ALI were elevated in the pre-exposure period, yet no such increased risks were observed following remdesivir initiation when compared to the pre-exposure period.

Keyphrases

acute kidney injury
liver injury
drug induced
human health
coronavirus disease
sars cov
cardiac surgery
risk assessment
respiratory syndrome coronavirus
liver failure
intensive care unit
aortic dissection
acute respiratory distress syndrome